Premature ovarian failure: A review

Climacteric

Volumn 10, Issue 1, 2007, Pages 11-22

  Nippita, T A ^a   Baber, R J ^a,b,c  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c North Shore Private Hospital   (Australia)

Author keywords

Hormone replacement; Premature menopause; Premature ovarian failure

Indexed keywords

ALKYLATING AGENT; ANDROGEN; ANTINEOPLASTIC AGENT; BONE MORPHOGENETIC PROTEIN 15; CHORIONIC GONADOTROPIN BETA SUBUNIT; ESTRADIOL; ESTROGEN; FOLLITROPIN RECEPTOR; FRAGILE X MENTAL RETARDATION PROTEIN; GALACTOSE 1 PHOSPHATE URIDYLYLTRANSFERASE; GESTAGEN; GONADOTROPIN; INHIBIN; LUTEINIZING HORMONE RECEPTOR; MUELLERIAN INHIBITING FACTOR; PROLACTIN; STEROID 17ALPHA MONOOXYGENASE;

AMENORRHEA; AUTOIMMUNE DISEASE; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; COCHRANE LIBRARY; COGNITION; DATA BASE; ENDOCRINE DISEASE; ESTROGEN DEFICIENCY; FEMALE INFERTILITY; FERTILIZATION IN VITRO; FRAGILE X SYNDROME; GENE DELETION; GENE MUTATION; HORMONE SUBSTITUTION; HUMAN; HYPERGONADOTROPINEMIA; INFECTION; MEDLINE; MENSTRUATION DISORDER; PREMATURE OVARIAN FAILURE; PREVALENCE; PRIORITY JOURNAL; RADIATION INJURY; REVIEW; SECONDARY AMENORRHEA; SMOKING; TRISOMY; TURNER SYNDROME; X CHROMOSOME;

EID: 33847149572     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.1080/13697130601135672     Document Type: Review

References (111)

1. de Morales-Ruehsen M, Jones GS. Premature ovarian failure. Fertil Steril 1967;18:440-61
2. Coulam CB, Adamson DC, Annegers JF. Incidence of premature ovarian failure. Obstet Gynecol 1986;67:604
3. Nelson LM, Covington SN, Rebar RW. An update: spontaneous premature ovarian failure is not an early menopause. Fertil Steril 2005;83:1327-32
4. Luborsky JL, Meyer P, Sowers MF, Gold EB, Santoro N. Premature menopause in a multi-ethnic population study of the menopause transition. Hum Reprod 2002;18:199-206
5. Cramer D, Xu H. Predicting age at menopause. Maturitas 1996;23:319-26
6. Anasti JN. Premature ovarian failure: an update. Fertil Steril 1998;70:1-15
7. Larsen EC, Muller J, Schmiegelow K, Rechnitzer C, Andersen AN. Reduced ovarian function in long-term survivors of radiationand chemotherapy-treated childhood cancer. J Clin Endocrinol Metab 2003;88:5307-14
8. Meirow D. Ovarian injury and modern options to preserve fertility in female cancer patients treated with high dose radio-chemotherapy for hemato-oncological neoplasias and other cancers. Leuk Lymphoma 1999;33:65-76
9. Blumenfeld Z, Eckman A. Preservation of fertility and ovarian function and minimization of chemotherapy-induced gonadotoxicity in young women by GnRH-a. J Natl Cancer Inst Monogr 2005;34:40-3
10. Franke H, Smit W, Vermes I. Gonadal protection by a gonadotropin releasing hormone agonist depot in young women with Hodgkins disease undergoing chemotherapy. Gynecol Endocrinol 2005;20:274-8
11. Madsen BL, Giudice L, Donaldson SS. Radiation-induced premature menopause: a misconception. Int Radiat Oncol Biol Phys 1995;32:1461-4
12. Beerendonk CC, Braat DD. Present and future options for the preservation of fertility in female adolescents with cancer. Endocr Dev 2005;8:166-75
13. Spinelli S, Chiodi S, Bacigalupo A, et al. Ovarian recovery after total body irradiation and allogenic bone marrow transplantation: long term follow up of 79 females. Bone Marrow Transplant 1994;14:373-80
14. Vegetti W, Tibiletti MG, Testa G, et al. Inheritance in idiopathic premature ovarian failure: analysis of 71 cases. Hum Reprod 1998;13:1796-800
15. Conway GS. Premature ovarian failure. Curr Opin Obstet Gynecol 1997;9:202-6
16. Woad KJ, Watkins WJ, Prendergast D, Shelling AN. The genetic basis of premature ovarian failure. Aust N Z J Obstet Gynaecol 2006;46:242-4
17. Shelling AN. X chromosome defects and premature ovarian failure. Aust N Z J Med 2000;30:5-7
18. Toniolo D. X linked premature ovarian failure: a complex disease. Curr Opin Genet Dev 2006;16:293-300
19. Zinn AR, Tonk VS, Chen Z, et al. Evidence for a Turner syndrome locus or loci at Xp112-p221. Am J Hum Genet 1998;63:1757-66
20. Holland CM. 47XXX in an adolescent with premature ovarian failure and autoimmune disease. J Paediatr Adolesc Gynecol 2001;14:77-80
21. Itu M, Neelam T, Ammini AC, Kucheria K. Primary amenorrhoea in a triple X female. Aust N Z J Obstet Gynaecol 1990;30:386-8
22. Hundscheid RDL, Sistermans EA, Thomas CMG, et al. Imprinting effect in premature ovarian failure confined to paternally inherited fragile X permutations. Am J Hum Genet 2000;66:413-18
23. Hagerman PJ, Hagerman RJ. The fragile-X premutation: a maturing perspective [published correction appears in Am J Hum Genet 2004;75:352]. Am J Hum Genet 2004;74:805-16
24. Rebar RW. Mechanisms of premature menopause. Endocrinol Metab Clin N Am 2005;34:923-33
25. Di Pasquale E, Beck-Peccoz P, Persani L. Hypergonadotrophic ovarian failure associated with an inherited mutation of human bone morphogenetic protein-15 (BMP15) gene. Am J Hum Genet 2004;75:159-66
26. Laml T, Preyer O, Umek W, Hengstschläger M, Hanzal E. Genetic disorders in premature ovarian failure. Hum Reprod Update 2002;8:483-91
27. Mallin SR. Congenital adrenal hyperplasia secondary to 17-hydroxylase deficiency: two sisters with amenorrhoea, hypokalemia, hypertension and cystic ovaries. Ann Intern Med 1969;70:69-75
28. Rabinovivi J, Blankstein J, Goldman B, et al. In vitro fertilisation and primary embryonic cleavage are possible in 17α-hydroxylase deficiency despite extremely low intrafollicular 17β-estradiol. J Clin Endocrinol Metab 1989;68:693-7
29. Aittomaki K, Lucena JLD, Parkarinen P, et al. Mutation in the follicle stimulating hormone receptor gene causes hereditary hypergonadotrophic ovarian failure. Cell 1995;82:959-68
30. Latronico AC, Anasti J, Arnhold IJ, et al. Brief report: testicular and ovarian resistance to luteinising hormone caused by inactivating mutations of the luteinising hormone-receptor gene. N Engl J Med 1996;334:507-12
31. Takahashi K, Karino K, Kanasaki H, et al. Influence of missense mutation and silent mutation of LH beta-subunit gene in Japanese patients with ovulatory disorders. Eur J Hum Genet 2003;11:402-8
32. Goswami D, Conway GS. Premature ovarian failure. Hum Reprod Update 2005;11:391-410
33. Santoro N. Research on the mechanisms of premature ovarian failure. J Soc Gynecol Investig 2001;8(1 Suppl Proceedings):S10-12
34. Forges T, Monnier-Barbarino P, Faure GC, Bene MC. Autoimmunity and antigenic targets in ovarian pathology. Hum Reprod Update 2004;10:163-75
35. Koyama K, Hasegawa A, Mochida N, Calongos G. Follicular dysfunction induced by autoimmunity to zona pellucida. Reprod Biol 2005;5:269-78
36. Di Prospero F, Luzi S, Iacopini Z. Cigarette smoking damages women's reproductive life. Reprod Biomed Online 2004;8:246-7
37. Cramer DW, Harlow BL, Xu H, Fraer C, Barbieri R. Cross-sectional and case-controlled analyses of the association between smoking and early menopause. Maturitas 1995;22:79-87
38. Mattison DR, Thorgeirsson SS. Smoking and industrial pollution, and their effects on menopause and ovarian cancer. Lancet 1978;i:187-8
39. Rebar RW, Coonolly HV. Clinical features of young women with hypergonadotropic amenorrhea. Fertil Steril 1990;53:804-810
40. Mocayo R, Moncayo HE. Premature ovarian failure: evidence of immunologic component. In Ovarian Autoimmunity: Clinical and Experimental Data, 1st edn. Austin, TX: RG Landes Co, 1995:27-75
41. Busacca M, Riparini JR, Somigliana E, et al. Post surgical ovarian failure after laparoscopic excision of bilateral endometriomas. Am J Obstet Gynecol 2006;195:421-5
42. Siddle N, Sarrel P, Whitehead M. The effect of hysterectomy on age at ovarian failure. Fertil Steril 1987;47:94-100
43. Alzubaidi NH, Chapin HL, Vanderhoof HV, Calis KA, Nelson LM. Meeting the needs of young women with secondary amenorrhea and spontaneous premature ovarian failure. Obstet Gynecol 2002;99:720-5
44. Biscotti CV, Hart WR, Lucas JG. Cystic ovarian enlargement resulting from autoimmune oophoritis. Obstet Gynecol 1989;74:492
45. Rebar RW, Erickson GF, Yen SSC. Idiopathic premature ovarian failure: clinical and endocrine characteristics. Fertil Steril 1982;37:35-41
46. Kim TJ, Anasti JN, Flack MR, Kimzey LM, Defensor RA, Nelson LM. Routine endocrine screening for patients with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol 1997;89:777-9
47. Falorni A, Laureti S, Candeloro P, et al. Steroid-cell autoantibodies are preferentially expressed in women with premature ovarian failure who have adrenal autoimmunity. Fertil Steril 2002;78:270-9
48. Bakalov BK, Vanderhoof VH, Bondy CA, Nelson LM. Adrenal antibodies detect asymptomatic autoimmune adrenal insufficiency in young women with spontaneous premature ovarian failure. Hum Reprod 2002;17:2096-100
49. Khastgir G, Abdalla H, Studd JW. The case against ovarian biopsy for the diagnosis of premature menopause. Br J Obstet Gynaecol 1994;101:96-7
50. Groff A, Covington S, Halverson L. Assessing the emotional needs of women with spontaneous premature ovarian failure. Fertil Steril 2005;83:1734-41
51. van Kasteren YM, Schoemaker J. Premature ovarian failure: a systematic review on therapeutic interventions to restore ovarian function and achieve pregnancy. Hum Reprod Update 1999;5:483-92
52. Pal L, Santoro N. Premature ovarian failure: discordance between somatic and reproductive ageing. Ageing Res Rev 2002;1:413-23
53. Kalantaridou S, Nelson L. Premature ovarian failure is not a premature menopause. Ann NY Acad Sci 2000;900:393-402
54. Demeestere I, Simon P, Englert Y, Delbaere A. Preliminary experience of ovarian tissue cryopreservation procedure: alternatives, perspectives and feasibility. Reprod Biomed Online 2003;7:572-9
55. Siegel-Itskovich J. Woman gives birth after receiving transplant of her own ovarian tissue. BMJ 2005;331:70
56. Meirow D, Levron J, Eldar-Geva T, et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemo therapy. N Eng J Med 2005;353:318-21
57. Donnez J, Dolmans MM, Demylle D, et al. Live birth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004;364:1405-10
58. Seli E, Tangir J. Fertility preservation options for female patients with malignancies. Curr Obstet Gynaecol 2005;17:299-308
59. Friden B, Hreinsson J, Hovatta O. Birth of a healthy infant after in vitro oocyte maturation and ICSI in a woman with diminished ovarian response: case report. Hum Reprod 2005;20:2556-8
60. Royal Australian and New Zealand College of Obstetricians and Gynaecologists. Advice for medical practictioners regarding the use of postmenopausal hormone therapy. August 2004
61. Royal College of Obstetricians and Gynaecologists. Consensus views arising from the 47th Study Group: Menopause and Hormone Replacement. November 2004
62. Bjarnason K, Cerin A, Lindgren R, Weber T. Adverse endometrial effects during long cycle hormone replacement therapy: Scandinavian Long Cycle Study Group. Maturitas 1999;32:161-70
63. Barrett-Connor E. The economic and human costs of osteoporotic fracture. Am J Med 1995;98(Suppl 2A):3-8s
64. Richelson LS, Wahner HW, Melton LJ, Riggs BL. Relative contributions of ageing and estrogen deficiency to postmenopausal bone loss. N Engl J Med 1984;311:1273-5
65. Nordin BEC, Need AG, Chatterton BE, Horowitz M, Morris HA. The relative contributions of age and years since menopause to postmenopausal bone loss. J Clin Endocrinol Metab 1990;70:83-8
66. Ahlborg HG, Johnell O, Nilsson BE, Jeppsson S, Rannevik G, Karlsson MK. Bone loss in relation to menopause: a prospective study during years. Bone 2001;28:327-31
67. Luisetto G, Zangari M, Tizian L, et al. Influence of aging and menopause in determining vertebral and distal forearm bone loss in adult healthy women. Bone Miner 1993;22:9-25
68. Hadjidakis DJ, Kokkinakis EP, Sfakianakis ME, Raptis SA. Bone density patterns after normal and premature menopause. Maturitas 2003;44:279-86
69. van der Voort DJM, van der Weijer PHM. Early menopause: increased fracture risk at older age. Osteoporos Int 2003;14:525-30
70. Writing Group for the Women's Health Initiative. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33
71. Van der Schouw YT, van der Graaf Y, Steyerberg EW, Eijkemans JC, Banga JD. Age at menopause as a risk factor for cardiovascular mortality. Lancet 1996;347:714-18
72. Cooper GS, Sandler DP. Age at natural menopause and mortality. Ann Epidemiol 1998;8:229-35
73. De Kleijn MJJ, van der Schouw YT, Verbeek ALM, Peeters PHM, Banga JD, van der Graaf Y. Endogenous estrogen exposure and cardiovascular mortality risk in postmenopausal women. Am J Epidemiol 2002;155:339-45
74. Jacobsen BK, Knutsen SF, Fraser GE. Age at natural menopause and total mortality and mortality from ischemic heart disease: the Adventist Health Study. J Clin Epidemiol 1999;52:303-7
75. Hu FB, Grodstein F, Hennekens CH, et al. Age at natural menopause and risk of cardiovascular disease. Arch Intern Med 1999;159:1061-6
76. Kalantaridou SN, Naka KK, Bechlioulis A, Makrigiannakis A, Michalis L, Chrousos GP. Premature ovarian failure, endothelial dysfunction and estrogen-progestogen replacement. Trends Endocrinol Metab 2006;17:101-9
77. Kalantaridou SN, Naka KK, Papanikolaou E, et al. Impaired endothelial function in young women with premature ovarian failure: normalisation with hormonal therapy. J Clin Endocrinol Metab 2004;89:3907
78. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med 1996;335:453-61
79. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 1998;280:605-13
80. Wassertheil-Smoller S, Hendrix SL, Limacher M, et al. Effect of estrogen plus progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-784
81. Kaplan JR, Adams MR, Anthony MS, Morgan TM, Manuck SB, Clarkson TB. Dominant social status and contraceptive hormone treatment inhibit atherogenesis in premenopausal monkeys. Atheroscler Thromb Vasc Biol 1995;15:2094-100
82. Clarkson TB, Anthony MS, Klein KP. Hormone replacement therapy and coronary artery atherosclerosis: the monkey model. Br J Obstet Gynaecol 1996;103(Suppl 13):53-7
83. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357-65
84. Salpeter S. Cardiovascular disease incidence and HRT use in younger and older women. Climacteric 2005;8:307-10
85. Grodstein F, Manson J, Stampfer M. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health 2006;15:35-44
86. Worboys S, Kotsopoulos D, Teede H, McGrath B, Davis SR. Evidence that parenteral testosterone therapy may improve endothelium-dependent and -independent vasodilation in postmenopausal women already receiving estrogen. J Clin Endocrinol Metab 2001;86:158-61
87. Stefanick M, Anderson G, Margolis K, et al. Effects of conjugated equine estrogens on breast cancer and mammographic screening in post menopausal women with hysterectomy. JAMA 2006;295:1647-57
88. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006;166:772-80
89. Bermudez JA, Moran C, Herrera J, Barahona E, Perez MC, Zarate A. Determination of the steroidogenic capacity in premature ovarian failure. Fertil Steril 1993;60:668-71
90. Doldi N, Belvisi L, Bassan M, Fusi FM, Ferrari A. Premature ovarian failure: steroid synthesis and autoimmunity. Gynecol Endocrinol 1998;12:23-8
91. Hartmann BW, Kirchengast S, Albrecht A, Laml T, Soregi G, Huber JC. Androgen serum levels in women with premature ovarian failure compared to fertile and menopausal controls. Gynecol Obstet Invest 1997;44:127-31
92. Davis S. Androgen replacement therapy in women: a commentary. J Clin Endocrinol Metab 1999;84:1886-91
93. Anasti JN, Kalantaridou SN, Kimzey LM, Defensor RA, Nelson LM. Bone loss in young women with karyotypically normal spontaneous premature ovarian failure. Obstet Gynecol 1998;91:12-15
94. Davis SR, McCloud P, Strauss BJG, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. Maturitas 1995;21:227-36
95. Barrett-Connor E, Young R, Notelovitz M, et al. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. J Reprod Med 1999;44:1012-20
96. Savvas M, Studd JW, Norman S, Leather AT, Garnett TJ, Fogelman I. Increase in bone mass after one year of percutaneous and oestradiol implants in post-menopausal women who have previously received long-term oral oestrogens. Br J Obstet Gynaecol 1992;99:757-60
97. Kalantaridou SN, Calis KA, Mazer NA, Godoy H, Nelson LM. A pilot study of an investigational testosterone transdermal patch system in young women with spontaneous premature ovarian failure. J Clin Endocrinol Metab 2005;90:6549-52
98. Davis SR, Burger HG. The role of androgen therapy. Best Pract Res Clin Endocrinol Metab 2003;17:165-75
99. Maki PM. Hormone therapy and cognitive function: is there a critical period for benefit? Neuroscience 2006;138:1027-30
100. Ross JL, Stefanatos GA, Kushner H, et al. The effect of genetic differences and ovarian failure: intact cognitive function in adult women with premature ovarian failure versus Turner syndrome. J Clin Endocrinol Metab 2004;89:1817-22
101. Shumaker SA, Legault C, Rapp SR, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative memory study: a randomized controlled trial. JAMA 2003;289:2651-62
102. Shumaker SA, Legault C, Rapp SR, et al. Conjugated equine estrogen and the incidence of probable dementia and mild cognitive impairment in postmenopausal women. The Women's Health Initiative memory study: a randomized controlled trial. JAMA 2004;291:2947-58
103. Resnick SM, Henderson VW. Hormone therapy and risk of Alzheimer disease: a critical time. JAMA 2002;288:2170-2
104. Faddy MJ, Gosden RG, Gougeon A, Richardson SJ, Nelson JF. Accelerated disappearance of ovarian follicles in mid-life: implications for forecasting menopause. Hum Reprod 1992;7:1342-6
105. Swanton A, Child T. Reproduction and ovarian ageing. J Br Menopause Soc 2005;11:126-31
106. Burger HG, Dudley EC, Hopper JL, et al. The endocrinology of the menopausal transition: a cross sectional study of a population based sample. J Clin Endocrinol Metab 1995;80:3537-45
107. Burger HG, Dudley EC, Hopper JL, et al. Prospectively measured levels of serum follicle stimulating hormone, estradiol and the dimeric inhibins during the menopausal transition in a population based cohort of women. J Clin Endocrin Metab 1999;84:4025-30
108. Visser JA, de Jong FH, Laven JSE, Themmen APN. Anti-mullerian hormone: a new marker for ovarian function. Reproduction 2006;131:1-9
109. de Vet A, Laven JS, de Jong FH, Themmen APN, Fauser BC. Antimullerian hormone serum levels: a putative marker for ovarian ageing. Fertil Steril 2002;77:357-62
110. Tremellen KP, Kolo M, Gilmore A, Lekamge DN. Antimullerian hormone as a marker of ovarian reserve. Aust N Z J Obstet Gynaecol 2005;45:20-4
111. Nelson HD, Helfand M, Woolf SH, Allan JD. Screening for postmenopausal osteoporosis: a review of the evidence for the US preventative services task force. Ann Intern Med 2002;137:529-41